Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL)

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 90-93

  Kavanaugh, Arthur ^a   Mease, Philip ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Dactylitis; Enthesitis; Golimumab; Psoriatic arthritis; TNF inhibitors

Indexed keywords

C REACTIVE PROTEIN; GOLIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DACTYLITIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; ENTHESITIS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS MODIFIED MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; EUROPE; FOOT MALFORMATION; HAND MALFORMATION; HOSPITALIZATION; IMMUNOLOGY; JOINT; METABOLISM; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CANADA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOOT DEFORMITIES, ACQUIRED; HAND DEFORMITIES, ACQUIRED; HUMANS; INJECTIONS, SUBCUTANEOUS; JOINTS; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84864401979     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120254     Document Type: Conference Paper

References (13)

1. Ceponis A, Kavanaugh A. Psoriatic arthritis: advances in therapy. Int J Adv Rheumatol 2011;9:45-55.
2. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;Suppl 1:i77-84.
3. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
4. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32. (Pubitemid 36135387)
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
6. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
7. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
8. Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidenced based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21. (Pubitemid 44025162)
9. Ritchlin C, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
10. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
11. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
12. Gutierrez M, Filippucci E, De Angelis R. A sonographic spectrum of psoriatic arthritis: "the five targets". Clin Rheumatol 2010;29:133-42.
13. Coates LC, McGonagle DM, Hodgson R, Kavanaugh AF, Qureshi AA, Fitzerald O, et al. Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:448-52.